FY2024 EPS Estimates for Pyxis Oncology Cut by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Analysts at HC Wainwright reduced their FY2024 EPS estimates for Pyxis Oncology in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($1.00) for the year, down from their previous forecast of ($0.89). HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q4 2024 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.46) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.44) EPS and FY2028 earnings at ($0.75) EPS.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04.

A number of other brokerages have also commented on PYXS. Stephens began coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 price target for the company. Royal Bank of Canada reissued an “outperform” rating and set a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, September 19th. Finally, Stifel Nicolaus began coverage on Pyxis Oncology in a report on Thursday, August 8th. They issued a “buy” rating and a $10.00 price objective for the company. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $9.57.

Pyxis Oncology Stock Performance

NASDAQ PYXS opened at $4.19 on Friday. Pyxis Oncology has a one year low of $1.35 and a one year high of $6.85. The stock has a 50-day moving average of $3.68 and a 200 day moving average of $3.66. The company has a market capitalization of $249.16 million, a price-to-earnings ratio of -4.07 and a beta of 1.27.

Hedge Funds Weigh In On Pyxis Oncology

Institutional investors and hedge funds have recently bought and sold shares of the stock. StemPoint Capital LP purchased a new stake in Pyxis Oncology in the first quarter worth about $7,643,000. Ikarian Capital LLC bought a new position in shares of Pyxis Oncology during the 1st quarter valued at approximately $7,082,000. Blue Owl Capital Holdings LP bought a new position in shares of Pyxis Oncology during the 2nd quarter valued at approximately $3,462,000. Millennium Management LLC increased its holdings in Pyxis Oncology by 125.3% in the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after acquiring an additional 743,499 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Pyxis Oncology during the 3rd quarter worth approximately $1,405,000. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.